drugset
drugset / Trial / NCT05877222

A Phase 1 Trial to Investigate the Biological Equivalence of 5 × 10 mg Tablets and 2 × 25 mg Tablets of Daridorexant in Healthy Male and Female Japanese Participants

NCT05877222 ↗

Phase 1 Completed 38 enrolled Idorsia Pharmaceuticals Ltd.
RandomizedCrossoverOpen-labelOther

Summary

A Phase 1 trial to investigate bioequivalence between 5 × 10 mg tablets and 2 × 25 mg tablets of daridorexant in healthy male and female Japanese participants

Timeline

Start
2023-06-23
Primary completion
2023-08-04
Completion
2023-08-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Daridorexant Small molecule 10 mg Oral
Subject Daridorexant Small molecule 25 mg Oral

Indications

No indication recorded.